Agents Used to Treat Parasitic Infections¶
Chapter 229 | Part 5: Infectious Diseases
KEY CLINICAL POINTS¶
- Parasitic infections affect over 50% of the global population, with highest prevalence in underdeveloped nations. Chemotherapy remains the most effective control method despite drug resistance challenges.
- Key drugs include 4-aminoquinolines (e.g., chloroquine, primaquine), benzimidazoles (e.g., albendazole), and artemisinin derivatives (e.g., artesunate).
- Drug resistance is a major issue, particularly with chloroquine-resistant malaria and antimonial-resistant leishmaniasis.
- Pregnancy and breastfeeding safety vary by drug: e.g., mefloquine is contraindicated in pregnancy, while atovaquone/proguanil is considered safe.
- Combination therapies (e.g., artemether-lumefantrine) are preferred to reduce resistance and improve efficacy.
1. DEFINITION & OVERVIEW¶
Parasitic infections are caused by protozoa, helminths, and ectoparasites. Chemotherapy remains the cornerstone of treatment, though drug resistance and cost barriers persist. Global initiatives target neglected tropical diseases and malaria.
Table 228-1: Parasitic Infections by Organ System¶
| Organ System | Signs/Symptoms | Parasite(s) | Geographic Distribution | Comments |
|---|---|---|---|---|
| Muscular System | Myalgias, myositis | Trichinella | Worldwide | Palpebral swelling; high-level eosinophilia |
| Bloodstream | Fever without localizing symptoms | Plasmodium | Tropics and subtropics | Consider in malarious areas |
| Bloodstream | Fever without localizing symptoms | Babesia | New England, US | Geographically limited |
| Bloodstream | Fever without localizing symptoms | T. brucei rhodesiense, T. brucei gambiense | Sub-Saharan Africa | Tsetse fly range |
| Bloodstream | Periodic fever with eosinophilia | Filariae | Asia, India | Chronic lymphangitis |
| Bloodstream | Hepatosplenomegal y, fever, wasting | L. donovani complex | Tropics and subtropics | AIDS-defining infection |
1.1 Scope of Parasitic Diseases¶
Over 50% of the global population is affected, with highest prevalence in underdeveloped regions. Malaria, schistosomiasis, and leishmaniasis are major burdens. Climate change and deforestation have expanded disease reach.
1.2 Therapeutic Challenges¶
Drug resistance, limited new agents, counterfeit medications, and misuse (e.g., for COVID-19) have increased treatment costs. Combination therapies are critical to mitigate resistance.
2. EPIDEMIOLOGY¶
Parasitic infections are endemic in tropical and subtropical regions. Malaria, schistosomiasis, and leishmaniasis are major contributors to global disease burden. Drug resistance and socioeconomic factors complicate control efforts.
2.1 Global Burden¶
Over 50% of the world's population is at risk. Malaria alone causes ~600,000 deaths annually. Underdeveloped nations bear the highest disease prevalence due to poor sanitation and limited healthcare access.
2.2 Risk Factors¶
Travel to endemic regions, immunocompromised states (e.g., HIV), and environmental exposure (e.g., contaminated water). Climate change and deforestation have expanded disease distribution.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Parasites cause disease through direct tissue damage, immune-mediated responses, and metabolic interference. Drug mechanisms target specific pathways (e.g., β -tubulin, heme polymerase). Resistance develops via genetic mutations and efflux pumps.
3.1 Drug Mechanisms¶
Albendazole inhibits β -tubulin polymerization. Artemisinin derivatives target heme polymerase. Quinolines disrupt hemozoin formation. Benzimidazoles inhibit microtubule assembly.
3.2 Resistance¶
Resistance mechanisms include reduced drug uptake (e.g., chloroquine-resistant Plasmodium), efflux pumps, and metabolic pathway alterations. Antimonials and artemisinin derivatives face growing resistance.
4. CLINICAL FEATURES¶
Symptoms vary by parasite and infection stage. Common presentations include fever, malaise, organomegaly, and neurological involvement. Differential diagnosis includes bacterial infections and other systemic diseases.
4.1 Common Presentations¶
Fever, myalgias, hepatosplenomegaly, and eosinophilia. Neurological symptoms (e.g., seizures, encephalopathy) may occur with cerebral malaria or trypanosomiasis.
4.2 Complications¶
Anemia, organ failure, and secondary infections. Severe malaria may cause cerebral malaria, acute renal failure, and hypoglycemia.
5. DIFFERENTIAL DIAGNOSIS¶
Distinguish parasitic infections from bacterial, viral, and autoimmune conditions. Key differentiators include geographic distribution, travel history, and specific symptoms (e.g., periodic fever for filariasis).
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnosis relies on microscopy, antigen detection, and molecular methods. Imaging (e.g., MRI for CNS involvement) and serology aid in specific infections.
6.1 Diagnostic Tests¶
Microscopy (blood smears for malaria), PCR for Leishmania, and antigen detection (e.g., rapid diagnostic tests for malaria).
6.2 Imaging¶
CT/MRI for visceral involvement (e.g., leishmaniasis), ultrasound for hepatic abscesses, and endoscopy for intestinal parasites.
7. MANAGEMENT & TREATMENT¶
Treatment varies by parasite and infection severity. Combination therapies are preferred to reduce resistance. Dosing, drug interactions, and safety in special populations (e.g., pregnancy) are critical considerations.
Table 229-1: Agents for Parasitic Infections¶
| Drug Class | Parasitic Infection(s) | Adverse Effects | Drug Interactions | Pregnancy Class | Breast Milk |
|---|---|---|---|---|---|
| 4-Aminoquinolin es | Malaria | Agranulocytosis, hepatotoxicity | None | Not assigned | Yes |
| 4-Aminoquinolin es | Malaria | Pruritus, nausea, vomiting | Antacids reduce chloroquine absorption | Not assigned | Yes |
| 4-Aminoquinolin es | Malaria | GI disturbances | None | Not assigned | Yes |
| 8-Aminoquinolin es | Malaria | Hemolysis in G6PD deficiency | Quinacrine potentiates toxicity | Contraindicated | Yes |
| Aminoalcohols | Malaria | Abdominal pain, ECG disturbances | Concomitant QT prolongers contraindicated | C | No |
| Aminoglycosides | Amebiasis | GI disturbances, nephrotoxicity | No major interactions | B | No |
| Amphotericin B | Leishmaniasis | Fever, hypokalemia, nephrotoxicity | Antineoplastics increase renal toxicity | B | No |
| Drug Class | Parasitic Infection(s) | Adverse Effects | Drug Interactions | Pregnancy Class | Breast Milk |
|---|---|---|---|---|---|
| Antimonials | Leishmaniasis | Arthralgias, pancreatitis, ECG changes | Antiarrhythmics increase cardiotoxicity | Not assigned | No |
| Artemisinin Derivatives | Malaria | Neurotoxicity, nausea | Mefloquine levels increased | Not assigned | Yes |
| Atovaquone | Malaria, babesiosis | Nausea, vomiting | Cimetidine inhibits metabolism | C | Yes |
| Benzimidazoles | Intestinal Helminths | Nausea, diarrhea | Cimetidine inhibits mebendazole | C | No |
| Benznidazole | Chagas Disease | Rash, leukopenia | No major interactions | Not assigned | No |
| Clindamycin | Babesiosis | Pseudomembra nous colitis | No major interactions | B | Yes |
| Dapsone | Leishmaniasis | Rash, anorexia | Rifampin lowers levels | C | Yes |
| Flubendazole | Gut Nematodes | GI disturbances | No major interactions | C | No |
| Fumagillin | Microsporidia | Thrombocytopen ia | No major interactions | No information | No |
| Ivermectin | Onchocerciasis | Hypotension, elevated transaminases | Food/beer increase bioavailability | C | Yes |
| Lumefantrine | Malaria | Nausea, vomiting | Mefloquine levels decreased | C | No |
| Metronidazole | Amebiasis | Nausea, metallic taste | Disulfiram-like reactions | C | Yes |
| Nitazoxanide | Cryptosporidiosi s | GI upset | Increases protein-bound drug levels | C | No |
| Praziquantel | Schistosomiasis | Abdominal pain, dizziness | No major interactions | C | Yes |
| Quinacrine | Giardiasis | Yellow discoloration, psychosis | Potentiates primaquine toxicity | X | No |
| Quinine | Malaria | Cinchonism, hypoglycemia | Cimetidine increases levels | X | Yes |
| Sulfonamides | Cyclosporiasis | Hyperkalemia, GI upset | Methotrexate clearance increased | C | Yes |
| Tetracyclines | Giardiasis | Photosensitivity, esophagitis | Warfarin effect prolonged | D | Yes |
| Tubifendazole | Fascioliasis | Abdominal cramps, diarrhea | No major interactions | C | No |
7.1 Drug Classes¶
4-Aminoquinolines (e.g., chloroquine), benzimidazoles (e.g., albendazole), artemisinin derivatives (e.g., artesunate), and antimonials (e.g., meglumine antimoniate).
7.2 Administration¶
Oral, parenteral, or topical routes. Dosing adjustments for renal/hepatic impairment (e.g., reduced doses for mefloquine in renal failure).
8. PROGNOSIS & COMPLICATIONS¶
Prognosis varies by parasite and treatment response. Complications include drug toxicity, secondary infections, and organ failure. Early diagnosis and combination therapy improve outcomes.
8.1 Treatment Outcomes¶
Most infections respond to antiparasitic drugs, but resistance and delayed treatment may lead to severe complications (e.g., cerebral malaria, renal failure).
8.2 Long-Term Effects¶
Chronic infections (e.g., schistosomiasis) may cause organ damage. Drug-induced toxicity (e.g., hepatotoxicity) requires monitoring.
9. SPECIAL CONSIDERATIONS¶
Pregnancy and breastfeeding safety vary by drug. Special populations (e.g., elderly, immunocompromised) require dose adjustments. Drug interactions and resistance patterns must be considered.
9.1 Pregnancy¶
Mefloquine and primaquine are contraindicated. Atovaquone/proguanil is considered safe. Chloroquine and quinine require caution.
9.2 Pediatrics¶
Dosing adjusted for weight. Certain drugs (e.g., ivermectin) are contraindicated in children <2 years.
10. KEY POINTS & CLINICAL PEARLS¶
- Use combination therapies to reduce resistance. 2. Monitor for drug interactions (e.g., CYP3A4 inhibitors/inducers). 3. Avoid mefloquine in patients with cardiac disease. 4. Test for G6PD deficiency before primaquine. 5. Use parenteral formulations for severe infections.